|Bid||352.8100 x 800|
|Ask||352.3600 x 1400|
|Day's Range||351.5200 - 356.0200|
|52 Week Range||249.1700 - 370.5700|
|PE Ratio (TTM)||25.21|
|Earnings Date||Jul 24, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||365.46|
News of positive clinical data for its Alzheimer’s study lifted the entire biotechnology sector. Oddly enough, markets largely ignored pharmaceutical stocks, choosing instead to invest in the riskier biotech sector. The following are Big Pharma stocks that should be on the radar of most investors.
Celgene Corporation (NASDAQ:CELG) stock looks attractive here, for a number of reasons. Celgene stock has sold off, losing about 43% of its value. Celgene touched a four-year low in May before a recent rebound. The decline leaves Celgene looking awfully cheap, at a little over 8.3x 2019 consensus EPS estimates.
One successful drug on the market. Two potential approvals on the way. Six big partners. But do the numbers add up to buying Ionis right now?
South Korea's top financial regulator said on Thursday contract drug manufacturer Samsung BioLogics Co violated accounting rules in a case involving a joint venture and that it will report the firm and its CEO to prosecutors for investigation. The decision came after a months-long probe of bookkeeping of BioLogics, an affiliate of Samsung Electronics , amid growing scrutiny of South Korea's family-owned conglomerates under the administration of President Moon Jae-in. Samsung's biodrug business has been touted as a new growth engine for South Korea's biggest conglomerate Samsung Group, which includes crown jewel Samsung Electronics, amid a slowdown in the global smartphone market.
Biogen's results from a phase II study in the much-pursued Alzheimer's disease was all over the biotech sector last week.
On Friday, Biogen (NASDAQ:BIIB) shares soared on news that one of its Alzheimer’s drug trials was showing tremendous promise. Specifically, BIIB stock jumped nearly 20% after an update on BAN-2401, a phase 2 drug that showed a statistically significant slowdown in the memory loss associated with Alzheimer’s. BAN-2401, an antibody that takes aim at the amyloid plaque in the brain that’s thought to be a key cause of Alzheimer’s, was cast into a questionable light late last year.
The clinical trial results are a big deal, but they don't necessarily make the pharmaceutical company's shares a good deal.
Should you immediately sell a stock when it breaks out but closes beneath the proper buy point? Not always. Here are some tips on when to sit tight and when to bail early.
on Friday before the opening bell and the huge upside price gap, noting that, "If you are long BIIB based on our prior recommendations you are probably smiling this morning. With prices nearly reaching my $370 price target on Friday another look is warranted on Biogen, which Jim Cramer discusses on Real Money today. The price action from 2014 could be considered a high level consolidation pattern that is breaking out on the upside.
Shares of Amgen also moved north as Wall Street's celebration of Biogen's news pushed many biotech stocks higher. Biogen Inc. shares were jumping on Friday, closing the day up almost 20% on high volume compared to usual. The company along with Eisai Co. Ltd. of Japan had announced positive results from an Alzheimer's study.
Biogen BIIB and partner Eisai announced that amyloid antibody BAN2401 has yielded positive data in a large Phase 2 study in Alzheimer's disease. Biogen's strategy has its roots in the 2003 merger of Biogen (multiple sclerosis drug Avonex) and Idec (cancer drug Rituxan).
On Friday, we got the labor report for the month of June, and the 213,000 jobs came in ahead of expectations calling for 195,000. This sent U.S. equities higher, a sigh of relief among investors. That’s got us looking at five more top stock trades for Monday:Top Stock Trades for Tomorrow #1: Biogen (BIIB)
Biogen Inc. shares surged more than 18% Friday after the biotechnology company and Tokyo-based Eisai Co. Ltd. announced positive results from a mid-stage trial of a treatment for Alzheimer’s disease. The final analysis at 18 months of the 856-patient Phase 2 clinical study of BAN2401 in early Alzheimer’s disease demonstrated statistically significant slowing in cognitive decline and reduction of amyloid beta accumulated in the brain, the companies said in a release late Thursday. Amyloid beta are the protein fragments that are found in the brains of patients suffering from the disease and that some believe cause it.
Biogen execs will have a good weekend. Massachusetts-based Biogen Inc. announced positive results of the Phase 2 of the study of their joint beta-amyloid antibody BAN2401 on Friday, marking an important milestone in the companies' quest to tackle Alzheimer's disease.
On Thursday night, Biogen announced surprise successful results from an Alzheimer's drug clinical trial that sent shares of the pharmaceutical company soaring. Alzheimer's drug research has been plagued by years of unrelenting failures, leading companies including Pfizer to give up the search for new compounds. Dementia experts have questioned the narrow focus from biotech companies on amyloid protein, but the Biogen progress with an amyloid-targeting drug may lead to renewed confidence in the search for similar drugs.